HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Follow-Up Questions
HLS Therapeutics Inc 'in CEO'su kimdir?
Mr. Craig Millian 2023 'den beri şirketle birlikte olan HLS Therapeutics Inc 'in Chief Executive Officer 'ıdır.
HLTRF hissesinin fiyat performansı nasıl?
HLTRF 'in mevcut fiyatı $4.02 'dir, son işlem günde 0% decreased etti.
HLS Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
HLS Therapeutics Inc Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
HLS Therapeutics Inc 'in mevcut piyasa değerlemesi $125.9M 'dir
HLS Therapeutics Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 8 analist HLS Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 3 tut, 0 sat ve 2 güçlü sat içermektedir
